You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion alongside IPOPI at the IPIC Congress in Madrid

The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus

read more 

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 
  1. CORPORATE - 14-11-2019

    Kedrion Biopharma Announces Completion of Enrollment for CARES10

    A Phase 3, Multi-Center Study to Assess a 10% Ig in Adults with Primary Immunodeficiency Disease

    read more 
  2. CORPORATE - 16-10-2019

    FSI SGR enters Kedrion share capital

    The company continues with its growth and development strategy

    read more 
  3. EVENTS - 30-09-2019

    Kedrion reaffirms its commitment for the global eradication of Rh disease

    A worldwide initiative for maternal and fetal health launches in Florence, Italy

    read more 

Pages

For more information please contact: pressoffice@kedrion.com